{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:59:04Z","timestamp":1788188344461,"version":"build-2803163510"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T00:00:00Z","timestamp":1595635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Slovenian Research Agency","doi-asserted-by":"publisher","award":["P1-0170"],"award-info":[{"award-number":["P1-0170"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,26]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The most common psychiatric complications due to dopaminergic treatment in Parkinson\u2019s disease are visual hallucinations and impulse control disorders. Their development depends on clinical and genetic factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We evaluated the simultaneous effect of 16 clinical and 34 genetic variables on the occurrence of visual hallucinations and impulse control disorders. Altogether, 214 Parkinson\u2019s disease patients were enrolled. Their demographic, clinical, and genotype data were obtained. Clinical and clinical-pharmacogenetic models were built by The Least Absolute Shrinkage and Selection Operator penalized logistic regression. The predictive capacity was evaluated with the cross-validated area under the receiver operating characteristic curve (AUC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The clinical-pharmacogenetic index for prediction of visual hallucinations encompassed age at diagnosis (OR\u2009=\u20090.99), rapid eye movement (REM) sleep behavior disorder (OR\u2009=\u20092.27), depression (OR\u2009=\u20091.0002), IL6 rs1800795 (OR\u2009=\u20090.99), GPX1 s1050450 (OR\u2009=\u20091.07), COMT rs165815 (OR\u2009=\u20090.69), MAOB rs1799836 (OR\u2009=\u20090.97), DRD3 rs6280 (OR\u2009=\u20091.32), and BIRC5 rs8073069 (OR\u2009=\u20090.94). The clinical-pharmacogenetic index for prediction of impulse control disorders encompassed age at diagnosis (OR\u2009=\u20090.95), depression (OR\u2009=\u20091.75), beta-blockers (OR\u2009=\u20090.99), coffee consumption (OR\u2009=\u20090.97), NOS1 rs2682826 (OR\u2009=\u20091.15), SLC6A3 rs393795 (OR\u2009=\u20091.27), SLC22A1 rs628031 (OR\u2009=\u20091.19), DRD2 rs1799732 (OR\u2009=\u20090.88), DRD3 rs6280 (OR\u2009=\u20090.88), and NRG1 rs3924999 (OR\u2009=\u20090.96). The cross-validated AUCs of clinical and clinical-pharmacogenetic models for visual hallucinations were 0.60 and 0.59, respectively. The AUCs of clinical and clinical-pharmacogenetic models for impulse control disorders were 0.72 and 0.71, respectively. The AUCs show that the addition of selected genetic variables to the analysis does not contribute to better prediction of visual hallucinations and impulse control disorders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Models could be improved by a larger cohort and by addition of other types of Parkinson\u2019s disease biomarkers to the analysis.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ijnp\/pyaa028","type":"journal-article","created":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T03:27:52Z","timestamp":1586834872000},"page":"496-504","source":"Crossref","is-referenced-by-count":14,"title":["Clinical and Clinical-Pharmacogenetic Models for Prediction of the Most Common Psychiatric Complications Due to Dopaminergic Treatment in Parkinson\u2019s Disease"],"prefix":"10.1093","volume":"23","author":[{"given":"Sara","family":"Reden\u0161ek","sequence":"first","affiliation":[{"name":"Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Jenko Bizjan","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia"},{"name":"University Children\u2019s Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Tro\u0161t","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vita","family":"Dol\u017ean","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,7,25]]},"reference":[{"key":"2020112601570477600_CIT0001","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3109\/10409238.2010.516740","article-title":"Survivin: a target from brain cancer to neurodegenerative disease","volume":"45","author":"Baratchi","year":"2010","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"2020112601570477600_CIT0002","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/jnc.13125","article-title":"Effects of the beta-adrenergic receptor antagonist propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat","volume":"134","author":"Bhide","year":"2015","journal-title":"J Neurochem"},{"key":"2020112601570477600_CIT0003","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1517\/14740338.2016.1130128","article-title":"A review of adverse events linked to dopamine agonists in the treatment of Parkinson\u2019s disease","volume":"15","author":"Ceravolo","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"2020112601570477600_CIT0004","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of Parkinson disease: a review","volume":"311","author":"Connolly","year":"2014","journal-title":"JAMA"},{"key":"2020112601570477600_CIT0005","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nrneurol.2009.62","article-title":"Hallucinations in Parkinson disease","volume":"5","author":"Diederich","year":"2009","journal-title":"Nat Rev Neurol"},{"key":"2020112601570477600_CIT0006","doi-asserted-by":"crossref","first-page":"Article 1","DOI":"10.1515\/1544-6115.1815","article-title":"Time dependent ROC curves for the estimation of true prognostic capacity of microarray data","volume":"11","author":"Foucher","year":"2012","journal-title":"Stat Appl Genet Mol Biol"},{"key":"2020112601570477600_CIT0007","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3389\/fneur.2019.00351","article-title":"Impulse control disorders in Parkinson\u2019s disease. a brief and comprehensive review","volume":"10","author":"Gatto","year":"2019","journal-title":"Front Neurol"},{"key":"2020112601570477600_CIT0008","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/bimj.200900028","article-title":"L1 penalized estimation in the Cox proportional hazards model","volume":"52","author":"Goeman","year":"2010","journal-title":"Biom J"},{"key":"2020112601570477600_CIT0009","volume-title":"MDS-UPDRS","author":"Goetz","year":"2008"},{"key":"2020112601570477600_CIT0010","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.gene.2016.05.035","article-title":"Association of the DISC1 and NRG1 genetic polymorphisms with schizophrenia in a Chinese population","volume":"590","author":"He","year":"2016","journal-title":"Gene"},{"key":"2020112601570477600_CIT0011","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3389\/fnut.2018.00133","article-title":"The impact of coffee and caffeine on multiple sclerosis compared to other neurodegenerative diseases","volume":"5","author":"Herden","year":"2018","journal-title":"Front Nutr"},{"key":"2020112601570477600_CIT0012","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2217\/pgs.15.147","article-title":"Survivin polymorphism is associated with disease activity in rheumatoid arthritis patients","volume":"17","author":"Jenko","year":"2016","journal-title":"Pharmacogenomics"},{"key":"2020112601570477600_CIT0013","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/tpj.2016.36","article-title":"Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis","volume":"17","author":"Jenko","year":"2017","journal-title":"Pharmacogenomics J"},{"key":"2020112601570477600_CIT0014","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"2020112601570477600_CIT0015","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/jnnp-2015-312848","article-title":"Clinical-genetic model predicts incident impulse control disorders in Parkinson\u2019s disease","volume":"87","author":"Kraemmer","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2020112601570477600_CIT0016","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/mds.22678","article-title":"Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson\u2019s disease","volume":"24","author":"Lee","year":"2009","journal-title":"Mov Disord"},{"key":"2020112601570477600_CIT0017","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/mds.27466","article-title":"Functional monoamine oxidase B gene intron 13 polymorphism predicts putaminal dopamine turnover in de novo Parkinson\u2019s disease","volume":"33","author":"L\u00f6hle","year":"2018","journal-title":"Mov Disord"},{"key":"2020112601570477600_CIT0018","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1474-4422(18)30127-3","article-title":"Risk factors for non-motor symptoms in Parkinson\u2019s disease","volume":"17","author":"Marinus","year":"2018","journal-title":"Lancet Neurol"},{"key":"2020112601570477600_CIT0019","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00702-018-1870-8","article-title":"Impulse control disorders in Parkinson\u2019s disease","volume":"125","author":"Marques","year":"2018","journal-title":"J Neural Transm (Vienna)"},{"key":"2020112601570477600_CIT0020","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jclinepi.2004.01.020","article-title":"Penalized maximum likelihood estimation to directly adjust diagnostic and prognostic prediction models for overoptimism: a clinical example","volume":"57","author":"Moons","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"2020112601570477600_CIT0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12017-017-8473-7","article-title":"Genetics and treatment response in Parkinson\u2019s disease: an update on pharmacogenetic studies","volume":"20","author":"Politi","year":"2018","journal-title":"Neuromolecular Med"},{"key":"2020112601570477600_CIT0022","article-title":"Effects of genetic variability in dopaminergic pathway on treatment response in Parkinson\u2019s disease.","volume-title":"Parkinson\u2019s disease","author":"Reden\u0161ek","year":"2018"},{"key":"2020112601570477600_CIT0023","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12974-019-1439-y","article-title":"Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson\u2019s disease","volume":"16","author":"Reden\u0161ek","year":"2019","journal-title":"J Neuroinflammation"},{"key":"2020112601570477600_CIT0024","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3389\/fphar.2019.00008","article-title":"Dopaminergic pathway genes influence adverse events related to dopaminergic treatment in Parkinson\u2019s disease","volume":"10","author":"Reden\u0161ek","year":"2019","journal-title":"Front Pharmacol"},{"key":"2020112601570477600_CIT0025","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3389\/fgene.2019.00461","article-title":"Clinical-pharmacogenetic predictive models for time to occurrence of levodopa related motor complications in Parkinson\u2019s disease","volume":"10","author":"Reden\u0161ek","year":"2019","journal-title":"Front Genet"},{"key":"2020112601570477600_CIT0026","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ajmg.b.32413","article-title":"Genetics of psychosis of Alzheimer disease","volume":"174","author":"Shah","year":"2017","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"2020112601570477600_CIT0027","volume-title":"R: A language and environment for statistical computing","author":"Team","year":"2018"},{"key":"2020112601570477600_CIT0028","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12031-014-0482-5","article-title":"Genetic variability testing of neurodevelopmental genes in schizophrenic patients","volume":"56","author":"Terzi\u0107","year":"2015","journal-title":"J Mol Neurosci"},{"key":"2020112601570477600_CIT0029","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/08039488.2016.1240230","article-title":"Neuronal nitric oxide synthase polymorphisms in obsessive-compulsive disorder","volume":"71","author":"Topaloglu","year":"2017","journal-title":"Nord J Psychiatry"},{"key":"2020112601570477600_CIT0030","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.pneurobio.2009.02.002","article-title":"Statins: mechanisms of neuroprotection","volume":"88","author":"van der Most","year":"2009","journal-title":"Prog Neurobiol"},{"key":"2020112601570477600_CIT0031","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/ajmg.b.31034","article-title":"The association of the dopamine transporter gene and the dopamine receptor 2 gene with delirium, a meta-analysis","volume":"153B","author":"van Munster","year":"2010","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"2020112601570477600_CIT0032","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1038\/tp.2015.46","article-title":"Caffeine increases striatal dopamine D2\/D3 receptor availability in the human brain","volume":"5","author":"Volkow","year":"2015","journal-title":"Transl Psychiatry"},{"key":"2020112601570477600_CIT0033","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.schres.2015.07.018","article-title":"Clinical studies of neuroinflammatory mechanisms in schizophrenia","volume":"176","author":"Watkins","year":"2016","journal-title":"Schizophr Res"},{"key":"2020112601570477600_CIT0034","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2165\/11318330-000000000-00000","article-title":"Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson\u2019s disease","volume":"27","author":"Wood","year":"2010","journal-title":"Drugs Aging"},{"key":"2020112601570477600_CIT0035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.brainres.2017.06.012","article-title":"Neuregulin-1 protects mouse cerebellum against oxidative stress and neuroinflammation","volume":"1670","author":"Xu","year":"2017","journal-title":"Brain Res"},{"key":"2020112601570477600_CIT0036","doi-asserted-by":"crossref","first-page":"W600","DOI":"10.1093\/nar\/gkp290","article-title":"SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies","volume":"37","author":"Xu","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"2020112601570477600_CIT0037","doi-asserted-by":"crossref","first-page":"0000000000014852","DOI":"10.1097\/MD.0000000000014852","article-title":"Effect of statins on Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"98","author":"Yan","year":"2019","journal-title":"Med"},{"key":"2020112601570477600_CIT0038","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12883-015-0316-2","article-title":"DRD and GRIN2B polymorphisms and their association with the development of impulse control behaviour among Malaysian Parkinson\u2019s disease patients","volume":"15","author":"Zainal Abidin","year":"2015","journal-title":"BMC Neurol"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyaa028\/33531195\/pyaa028.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/23\/8\/496\/34544753\/pyaa028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/23\/8\/496\/34544753\/pyaa028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T22:55:28Z","timestamp":1722725728000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/23\/8\/496\/5876239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,25]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,11,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyaa028","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8]]},"published":{"date-parts":[[2020,7,25]]}}}